![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Effect of Primary Elvitegravir Resistance Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication Fitness
|
|
|
Reported by Jules Levin
International Workshop on HIV &
Hepatitis Virus Drug Resistance and Curative Strategies
June 5-9, 2012, Sitges, Spain
ME Abram, RM Hluhanich, DD Goodman, KN Andreatta, NA Margot, L Ye,
J Cavanaugh, A Niedziela-Majka, T Barnes, N Novikov, X Chen, ES Svarovskaia, DJ McColl, KL White and MD Miller
Gilead Sciences, Inc., California, USA
![resistance1.gif](../images/061812/061812-1/resistance1.gif)
![resistance2.gif](../images/061812/061812-1/resistance2.gif)
![resistance3.gif](../images/061812/061812-1/resistance3.gif)
![resistance4.gif](../images/061812/061812-1/resistance4.gif)
![resistance5.gif](../images/061812/061812-1/resistance5.gif)
![resistance6.gif](../images/061812/061812-1/resistance6.gif)
![resistance7.gif](../images/061812/061812-1/resistance7.gif)
![resistance8.gif](../images/061812/061812-1/resistance8.gif)
![resistance9.gif](../images/061812/061812-1/resistance9.gif)
![resistance10.gif](../images/061812/061812-1/resistance10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|